

DIVERSIFICATION DASHBOARD

May 2016


Diversification Ratios

TOBAM's Diversification Ratio (DR) measures to what extent a portfolio is diversified. The DR ² (square of the diversification ratio) measures the number of effective degrees of freedom to which a portfolio is exposed. As the table shows, the "broad market" indices leave diversification on the table. In addition to a snapshot of each market's DR2, the table shows the DR2 of a well-diversified portfolio, and the fraction of available diversification used by the index.	Universes	DR ² Index diversification	DR ² Maximum diversification	% diversification used by index
		MSCI All Countries World	3.83	10.69
	MSCI World	3.54	10.63	33.29%
	MSCI Canada	3.30	7.70	42.82%
	MSCI Emerging Markets	3.84	7.20	53.30%
	MSCI US Equity	2.44	5.60	43.49%
	MSCI Pacific Ex-Japan	2.17	4.81	45.19%
	MSCI UK Equity	2.07	3.35	61.68%
	MSCI EMU	1.69	3.21	52.48%
	MSCI Japan	1.78	2.91	61.22%
	BofA Merrill Lynch US Corporate & High Yield	2.80	3.77	74.10%

Source: TOBAM, figures as of March 31st, 2016

The Benefits of Diversification: Case of Japanese Equities in Q1 2016

Since the Yen reached its cheapest level in years vs. the USD in June 2015 (JPY/USD: 126), the Japanese currency has been steadily appreciating against the USD reaching its highest price in 18 months in April 2016 (JPY/USD: 109). While the current price remains low when compared to historical levels (5 years average is 98), this recent rally of the Yen was a twist in market trend seen for the first time since the re-election of Shinzo Abe as Japan's prime minister in December 2012. Amid a strengthening Yen, concerns on Japan's economy and the effectiveness of Abenomics, Japanese equities experienced their most volatile quarter in 7 years with the MSCI Japan's volatility reaching 38% in Q1 2016 – levels last seen during the financial crisis of 2008-Q12009:




The right hand axis has been reversed in order to illustrate the recent appreciation of the JPY vs. the USD. Source TOBAM.

In this market backdrop, Japanese equities plunged in Q1 2016, with the MSCI Japan index returning -12.66%. The Anti-Benchmark Japan strategy provided significant protection on the downside and outperformed its benchmark by +11.30%. In addition to its outperformance, the Anti-Benchmark reduced volatility vs. the MSCI Japan by 17%.

In this edition of the Diversification Dashboard we will investigate the drivers which led to the outperformance of the Anti-Benchmark portfolio in Japanese equities in Q1 2016.

1. Q1 2016: Performance Overview

Exhibit1: MSCI Japan TR vs. Anti-Benchmark Japan.



Source TOBAM. Past performance is not indicative of future results. Returns are stated in JPY and are gross of management fees.

As illustrated in the chart above, in Q1 2016, the Anti-Benchmark Japan returned -1.36% vs. -12.66% for the MSCI Japan, outperforming its benchmark by +11.30% and reducing volatility vs. the benchmark by 17%. Of note, the low beta of the Anti-Benchmark (0.81) explains only 21% of the outperformance; in the following section we will look at other dimensions in order to explain the relative return over the period.

In terms of market direction the quarter could be split in two periods:

- **Period 1** - from the opening of the year to February 12, the MSCI Japan fell by -22.85%, one of the largest down-moves in equities globally. During this period, the Anti-Benchmark outperformed by +9.65% and reduced volatility by 13%. The drop in Global Equities during this period was spurred by the collapse of Chinese equities and oil prices - global equities markets experienced a classical "risk-off" move. This was compounded by specific concerns on the Japanese economy and the effectiveness of Abenomics.
- **Period 2** - after February 12 to the end of the quarter, the MSCI Japan rallied by +13.22%. The market rally was driven by a more accommodative stance by Central banks in response to the global market and economic instability – including the Bank of Japan adopting a negative rate policy. During this period, the Anti-Benchmark Japan performed in line with the index (+13.65%) while also reducing volatility by 21% vs. the MSCI Japan.

In this note, we will focus on Period 1, during which the bulk of the outperformance was registered.


2. Drivers of Performance: Companies exposure to JPY/USD rates.

The first arrow of Mr. Abe's program about monetary stimulus mainly benefited export companies with the sharp depreciation of the Yen in recent years. We will analyse in this section the impact of the recent rapid rally of the Yen (a twist in market trend) on the performance of different company profiles in the Japanese equity market.

Exhibit 2 illustrates the return of all stocks of the MSCI Japan universe ranked by their correlation to the changes in JPY/USD rates over the past 12 months:

- Highly correlated stocks tend to benefit from a depreciating Yen (increase in JPY/USD rates): typically exporters which have a considerable portion of their revenues coming from abroad (such as Automakers, Financials, etc.).
- Lowly correlated assets are less dependent from the fluctuation of the FX rates as their revenues are coming from other sources of risk ("domestic" companies).

Exhibit 2: Period 1 – Return of Japanese Equities Ordered by their Correlation to JPY/USD.



Source TOBAM. Returns are stated in JPY – Past performance is not indicative of future results. Correlations are computed using 1 year daily data (13/02/2015 – 12/02/2016).

Over the period under review, companies that were more correlated to the fluctuation of the JPY/USD displayed on average a lower return than companies which were less dependent from the fluctuation of the FX rates.

To complement the above analysis, the following tables split the universe by tercile based on the stocks correlation to JPY/USD and compare the allocation of both the MSCI Japan and the Anti-Benchmark Japan for each bucket:

Exhibit 3:

Period1 – Japanese Equities Split in Tercile based on their Correlation to JPY/USD.

Correlation to JPY/USD	MSCI Japan Average Weight	AB Japan Average Weight	Delta Weight	Average Return	Relative Return Allocation Effect
1 - Low Correlation	24.41%	77.23%	52.82%	-16.28%	2.63%
2	28.07%	19.33%	-8.74%	-21.70%	0.04%
3 - High Correlation	47.53%	3.41%	-44.12%	-25.80%	2.00%
Grand Total	100.00%	99.96%	0.04%	-21.26%	4.67%

Source TOBAM. Returns are stated in JPY – Past performance is not indicative of future results. Correlations are computed using 1 year daily data (13/02/2015 – 12/02/2016).

Analysing the different dimensions of the above table:

a. Weights:

- The MSCI Japan index was biased toward stocks that are the most correlated to the fluctuation of the JPY/USD. 47.53% of its weight was allocated toward stocks belonging to the high correlation tercile.
- ⇒ Of note the bias of the MSCI Japan toward “Exporters” can be explained by several consecutive years of accommodative environment for Exporting companies which benefited from the Yen devaluation: the cap-weighted is a buy-and-hold strategy which by construction concentrates in past winners (refer to the **Appendix – Exhibit 4**).
- On the contrary the Anti-Benchmark portfolio had an important allocation to stocks which:
 - o Are less exposed to the fluctuation of JPY/USD rates.
 - o Are exposed to other **diverse*** sources of risk.

** (refer to Appendix – Exhibit 5): An intuitive way to illustrate the diversified exposure to sources of risk in the low correlation buckets, consist in comparing the GICS sectors of the first and tenth decile – where respectively the Anti-Benchmark and the MSCI Japan had their highest allocation.*

b. Returns:

- Stocks that displayed high correlation to the JPY/USD rates significantly underperformed (on average) stocks that were less exposed to the fluctuation of JPY/USD rates: stocks belonging to the high correlation tercile underperformed by -9.51% on average the stocks belonging to the “low correlation” tercile.
- Over the period, the higher the correlation to the JPY/USD rates, the lower on average was the return of a stock.

c. Relative Return - Explanatory Power:

- Over period 1, the Anti-Benchmark Japan (-13.20%), outperformed the MSCI Japan (-22.85%) by +9.65%.
- The allocation effect by tercile was equal to +4.67%. In other terms, roughly 50% of the excess return is explained just by looking at this specific dimension.

3. Conclusion

Amid an accommodative monetary policy which led to significant devaluation of the Yen in recent years, the MSCI cap-weighted benchmark was trapped (as a result of its buy-and-hold strategy) with an overexposure to Export companies which collapsed on the verge of a market correction. The first quarter of 2016 is a good illustration of how a diversified portfolio can protect investors from the implicit dynamic bets implemented by a cap-weighted investment....a passive investor in the Japanese equity markets is currently highly exposed to the fluctuation of JPY’s FX rates.


Of note, over the past 5 years, as of April 28th, 2016:

	MSCI Japan	Anti-Benchmark Japan	Difference
Total return	67.54%	97.06%	+29.52%
Annualized Return	10.87%	14.53%	+ 3.66%
Volatility	22.30%	16.73%	-25%
Sharpe Ratio	0.51	0.86	+0.35

Source TOBAM. Past performance is not indicative of future results. Returns are stated in JPY and are gross of management fees.

Appendix


Exhibit 4:
MSCI Japan - Rolling Weights in the First and Third Tercile based on Stocks' Correlation to JPY/USD rates.



Source TOBAM. Correlations are computed using 1 year daily data.

Exhibit 5:
1st vs. 10th Decile – GICS Sectors: Allocation of an Equal Weighted Portfolio (MSCI Japan Universe)

In the following table we compare the allocation of an equal weighted portfolio (MSCI Japan universe) for each of the first and last decile by GICS sectors. Stocks are grouped into deciles based on their correlation to the JPY/USD rates.



Source TOBAM. Weights are computed using an Equal Weighted allocation by stock. Correlations are computed using 1 year daily data.

The charts above indicate that:

- Stocks included in the highest correlation decile correspond mainly to three sectors: Financials, Consumer Discretionary and Industrials (and marginally to Health Care).
- On the contrary the first decile includes a much more diversified exposure with companies belonging to various sectors.



For more information

TOBAM is an asset management company offering innovative investment capabilities whose aim is to maximize diversification. TOBAM's Maximum Diversification® approach, supported by original, patented research and a mathematical definition of diversification, provides clients with diversified core exposure, in both the equity and fixed income markets. The company manages \$8 billion (March 2015) via its Anti-Benchmark® strategies in Equities and Fixed Income. Its team includes 41 investment professionals.

Contacts:

Paris

Christophe Roehri
+33 1 53 23 41 60
Christophe.Roehri@tobam.fr

New York

Stephane Detobel
+1 212 468 5171
stephane.detobel@tobamusa.com

Francis Verpoucke
+1 212 468 5170
francis.verpoucke@tobamusa.com

Hong Kong

Christopher Cheung
+852 2827 3894
christopher.cheung@tobamasia.com

Cape Town

Michael Gran
+44 7796 953 113
michael.gran@tobam.fr

Client Service

+33 1 53 23 41 66
ClientService@tobam.fr

Disclaimer

This material is solely for the attention of institutional, professional, qualified or sophisticated investors and distributors. It is not to be distributed to the general public, private customers or retail investors in any jurisdiction whatsoever. This document is intended only for the person to whom it has been delivered.

Funds and/or SICAV specific information may have been provided for information solely to illustrate TOBAM's expertise in the strategy. Funds or the SICAV that might be mentioned in this document may not be eligible for sale in some states or countries and they may not be suitable for all types of investors. In particular, TOBAM funds are not registered for sale in the US, and this document is not an offer for sale of funds to US persons (as such term is used in Regulation S promulgated under the 1933 Act). This material is provided for information purposes only and does not constitute a recommendation, solicitation, offer, advice or invitation to purchase or sell any fund, SICAV or sub-fund or to enter in any transaction and should in no case be interpreted as such, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract for the same.

The information provided in this presentation relates to strategies managed by TOBAM, a French investment adviser registered with the U.S. Securities and Exchange Commission (SEC) under the U.S. Investment Advisers Act of 1940 and the Autorité des Marchés Financiers (AMF) and having its head office located at 49-53 avenue des Champs Elysées, 75008 Paris, France. TOBAM's Form ADV is available free of charge upon request. In Canada, TOBAM is acting under the assumed name "Tobam SAS Inc." in Alberta and "TOBAM Société par Actions Simplifiée" in Québec.

Investment involves risk. All investors should seek the advice of their legal and/or tax counsel or their financial advisor prior to any investment decision in order to determine its suitability. The value and income produced by a strategy may be adversely affected by exchange rates, interest rates, or other factors so that an investor may get back less than he or she invested.

Past performance and simulations based on thereon are not indicative of future results nor are they reliable indicators of future performance. Any performance objective is solely intended to express an objective or target for a return on your investment and represents a forward-looking statement. It does not represent and should not be construed as a guarantee, promise or assurance of a specific return on your investment. Actual returns may differ materially from the performance objective, and there are no guarantees that you will achieve such returns. Back tests do not represent the results of an actual portfolio, and TOBAM does not guarantee the accuracy of supporting data. The constraints and fees applicable to an actual portfolio would affect results achieved.

This material, including back tests, is based on sources that TOBAM considers to be reliable as of the date shown, but TOBAM does not warrant the completeness or accuracy of any data, information, opinions or results. TOBAM has continued and will continue its research efforts amending the investment process from time to time accordingly. TOBAM reserves the right of revision or change without notice, of the universe, data, models, strategy and opinions. TOBAM accepts no liability whatsoever, whether direct or indirect, that may arise from the use of information contained in this material. TOBAM can in no way be held responsible for any decision or investment made on the basis of information contained in this material. The allocations and weightings, as well as the views, strategies, universes, data, models and opinions of the investment team, are as of the date shown and are subject to change.

This document and the information herein is disclosed to you on a confidential basis and shall not be reproduced, modified, translated or distributed without the express written permission of TOBAM or TOBAM NORTH AMERICA and to the extent that it is passed on, care must be taken to ensure that any reproduction is in a form which accurately reflects the information presented here. This information could be presented by TOBAM NORTH AMERICA, a wholly-owned subsidiary of the TOBAM group of companies that is authorized to present the investment strategies of TOBAM, subject to TOBAM's supervision, but is not authorized to provide investment advice.

Copyrights: All text, graphics, interfaces, logos and artwork, including but not limited to the design, structure, selection, coordination, expression, "look and feel" and arrangement contained in this presentation, are owned by TOBAM and are protected by copyright and various other intellectual property rights and unfair competition laws. Trademarks: "TOBAM," "MaxDiv," "Maximum Diversification," "Diversification Ratio," "Most Diversified Portfolio," "Most Diversified Portfolios," "MDP" and "Anti-Benchmark" are registered trademarks. The absence of a product or service name from this list does not constitute a waiver of TOBAM trademark or other intellectual property rights concerning that name. Patents: The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are patented or patent pending. Knowledge, processes and strategies: The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are protected under unfair competition, passing-off and misappropriation laws. Terms of use: TOBAM owns all rights to, title to and interest in TOBAM products and services, marketing and promotional materials, trademarks and Patents, including without limitation all associated Intellectual Property Rights. Any use of the intellectual property, knowledge, processes and strategies of TOBAM for any purpose and under any form (known and/or unknown) in direct or indirect relation with financial products including but not limited to certificates, indices, notes, bonds, OTC options, warrants, mutual funds, ETFs and insurance policies (i) is strictly prohibited without TOBAM's prior written consent and (ii) requires a license.

JKYCTFLVTCR